Pacific Biosciences of California Inc

2026-11-11 23:01; UTC

Pacific Biosciences of California, Inc. is trading higher in after-market hours, maintaining a cumulative return since Wednesday's close amid a broader market rise.

2026-11-10 22:01; UTC

Pacific Biosciences announces a sales agreement with Allen & Co. for up to $100 million in common stock through an at-the-market equity offering program.

2026-11-09 21:03; UTC

Pacific Biosciences is advancing sharply, reaching its highest cumulative return since Friday, despite initial volatility earlier in the session.

2026-11-07 00:01; UTC

Pacific Biosciences of California, Inc. shares are trading modestly lower in after-market hours, continuing a trend of lower closes over the past three sessions.

2026-11-06 23:41; UTC

Pacific Biosciences of California, Inc. is trading modestly lower in after-market hours, marking its fourth consecutive session of declines.

2026-11-05 23:36; UTC

ARK Genomic Revolution ETF declined in after-market trading as several holdings reported larger-than-expected net losses, with Pacific Biosciences also falling modestly.

2026-11-04 23:31; UTC

Pacific Biosciences reports Q3 revenue of $40.6 million, exceeding expectations, and narrows 2026 revenue guidance to $155 million to $160 million.

2026-11-03 23:41; UTC

Pacific Biosciences is advancing in after-market trading, supported by positive economic indicators and a broadly higher market, despite mixed earnings from Apple.

2026-11-02 23:11; UTC

Pacific Biosciences of California, Inc. is seeing notable strength in after-market trading, recovering from a low point shortly after the market closed.

2026-10-31 00:01; UTC

In after-market trading, Pacific Biosciences of California, Inc. has advanced sharply since Friday's close, remaining well above its 20-day moving average.

2026-10-30 23:41; UTC

Pacific Biosciences is advancing in after-market trading, reaching a high that significantly exceeds Friday's close and is well above its 20-day moving average.

2026-10-29 23:01; UTC

Pacific Biosciences of California, Inc. is trading lower in after-market hours, reflecting a broader market decline influenced by disappointing earnings from Illumina.

2026-10-28 23:02; UTC

Pacific Biosciences of California, Inc. is trading lower in after-market hours, reflecting the broader market's decline following the Fed's interest rate decision.

2026-10-27 23:06; UTC

Pacific Biosciences of California, Inc. is trading modestly lower in after-market hours, continuing a downward trend despite strong performance over the past month.

2026-10-26 23:06; UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, retracing from an earlier gain, despite a strong one-month performance.

2026-10-23 19:16; UTC

Pacific Biosciences of California Inc is trading roughly flat, showing little change since Thursday's close, while remaining below its 20-day moving average.

2026-10-22 19:56; UTC

Pacific Biosciences of California Inc shares fell, influenced by declines in the ARK Genomic Revolution ETF and its holdings, including 10X Genomics and Illumina.

2026-10-21 23:16; UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours, marking its fifth consecutive session of gains.

2026-10-20 23:16; UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours following Tuesday's close, amid ongoing volatility within its one-month trading range.

2026-10-19 20:07; UTC

Pacific Biosciences announces a multi-year collaboration with Verily Health to integrate HiFi sequencing technology with Verily's AI platform for clinico-genomic datasets.

2026-10-16 23:06; UTC

Pacific Biosciences of California Inc is effectively unchanged in after-market trading, having retraced from earlier highs amid recent declines below its 20-day moving average.

2026-10-15 23:02; UTC

After-market hours, the ARK Genomic Revolution ETF (ARKG) is trading higher, supported by a Neutral rating for CRISPR Therapeutics from UBS and gains in key holdings.

2026-10-14 23:21; UTC

Pacific Biosciences shares declined in after-market trading, marking the fourth consecutive session of lower prices, reaching a recent low shortly before the latest timestamp.

2026-10-13 23:06; UTC

Pacific Biosciences of California Inc's shares were roughly flat in after-market trading, following three consecutive lower daily closes while remaining above the 20-day moving average.

2026-10-12 22:16; UTC

Pacific Biosciences of California Inc is trading roughly flat in after-market hours, with the stock positioned around the middle of its one-month range.

2026-10-09 20:07; UTC

UBS initiated coverage of Pacific Biosciences with a Neutral rating and a price target of $1.35, adjusting its Fair Value estimate to $2.40 per share.

2026-10-08 23:20; UTC

Pacific Biosciences shares declined significantly in after-market trading, reversing earlier gains and marking a notable drop compared to Thursday's close.

2026-10-07 23:06; UTC

Pacific Biosciences of California Inc declined during after-market hours on Wednesday, retracing significantly from its prior close despite strong recent performance.

2026-10-06 23:06; UTC

Pacific Biosciences of California Inc declined in after-market trading, moving lower since Tuesday's close, despite strong performance over the past month.

2026-10-05 20:03; UTC

Pacific Biosciences of California Inc is higher in Monday's trading, continuing its upward trend since Friday, despite earlier pulling back from a session high.